The prestigious Fierce 15 biotech award has come to symbolize novelty and being at the forefront of biotechnology development amongst privately held businesses. The winners of this award are aiming at breakthroughs and big things, not at being ‘me-too’.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
For years, 1stOncology has taken special interest in those awardees with positions in oncology or whose technologies we deem beneficial in the oncology area. With oncology being one of the fastest growing therapeutic fields, it comes as no surprise that eleven out of the fifteen 2017 Fierce 15 Biotech Award winners are oncology companies. The majority are U.S. based (8), originating from Massachusetts (4), California (2), New Jersey (1) and Texas (1). Two companies are based in Canada and one in the United Kingdom.
| Awardee | Founded | Country |
| PsiOxus Therapeutics | 2006 | United Kingdom |
| PMV Pharma | 2013 | USA |
| Rubius Therapeutics | 2014 | USA |
| Vividion Therapeutics | 2014 | USA |
| Gritstone Oncology | 2015 | USA |
| Turnstone Biologics | 2015 | Canada |
| Aravive Biologics | 2016 | USA |
| Magenta Therapeutics | 2016 | USA |
| Relay Therapeutics | 2016 | USA |
| Repare Therapeutics | 2016 | Canada |
| Tango Therapeutics | 2017 | USA |
These companies were all founded between 2006 and as recent as this year. PsiOxus Therapeutics is the oldest company with Tango Therapeutics being the new kid on the block. Most of the companies were founded in 2016.
Many of them have recently secured financing, like Magenta Therapeutics ($50 million (2017)), PMV Pharma ($74 million (2017)), Rubius Therapeutics ($120 million (2017)), Tango Therapeutics ($55 million (2017)) and Relay Therapeutics ($57 million (2016)).
Among the technologies and discovery engines of the above companies we find gene editing, oncolytic viruses, synthetic lethality and neoantigen-based immunotherapies etc. Target interest falls on traditional hot areas such as tumor adoptive responses, oncogenic drivers, tumor suppressor gene loss and immune evasion, but also new avenues are being explored like the Unfolded Protein Response (UPR) pathway etc.
Morover, Rubius Therapeutics is developing Red-Cell Therapeutics (RCTs) as a new class of medicines for the treatment of cancer and albeit not specifically talking about oncology, Vividion Therapeutics is developing drugs based on technology that radically expands the druggability of the human proteome.
Interested in understanding and surveying the pipelines and progress of these best and brightest award winners, not only from this year, but back to 2010? We would like to welcome you to join us for a free 30 minute 1stOncology demo to show you the difference 1stOncology can make in your day to day work.